Figure 4.
Impact of orally administered tofacitinib on peripheral immune populations in mice. WT control mice (half male and half female) were treated for two weeks with low- (5 mg/kg) and high- (30 mg/kg) dose tofacitinib administered in standard chow. Immune cells were then analyzed in peripheral blood using flow cytometry; (A) percentage of all CD45+ immune cells as well as (B) total numbers of cells was examined for six immune populations. Data show mean ± SEM. Comparisons by ANOVA; n = 4 mice per group. *P<0.05, **P<0.01, ***P<0.001; monos, monocytes.